Prolonged Disease Stability with Durvalumab and Tremelimumab Rechallenge Following Prior Immune Checkpoint Inhibitors: A Case Report
Oncology Research · 2026 · 1-10
DOI: 10.32604/or.2026.083193 ↗Kurz gefasst
Fallbericht in der Zeitschrift Oncology Research, 2026. Verfasst von Waseem Abdelrahim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Michael E. DeBakey HS for Health Professions, Houston, TX, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Liver Neoplasms, Antibodies, Monoclonal, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Michael E. DeBakey HS for Health Professions, Houston, TX, USA.
- Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX, USA.
- College of Natural Sciences, University of Houston, Houston, TX, USA.
Zitieren
APA
Abdelrahim, W., Al-Najjar, E., El Beheary, S., & Esmail, A. (2026). Prolonged Disease Stability with Durvalumab and Tremelimumab Rechallenge Following Prior Immune Checkpoint Inhibitors: A Case Report. Oncology Research, 0(0), 1-10. https://doi.org/10.32604/or.2026.083193
Vancouver
Abdelrahim W, Al-Najjar E, El Beheary S, Esmail A. Prolonged Disease Stability with Durvalumab and Tremelimumab Rechallenge Following Prior Immune Checkpoint Inhibitors: A Case Report. Oncology Research. 2026;0(0):1-10. doi:10.32604/or.2026.083193
BibTeX
@article{Abdelrahim2026,
author = {Abdelrahim, Waseem and Al-Najjar, Ebtesam and El Beheary, Seif and Esmail, Abdullah},
title = {Prolonged Disease Stability with Durvalumab and Tremelimumab Rechallenge Following Prior Immune Checkpoint Inhibitors: A Case Report},
journal = {Oncology Research},
year = {2026},
volume = {0},
number = {0},
pages = {1--10},
doi = {10.32604/or.2026.083193}
}
EUVIMED